Objectives: To review evidence from systematic reviews and/or meta-analyses (SR/MAs) regarding neuraminidase inhibitor (NI) safety and effectiveness.
Introduction
Pandemic influenza remains a major public health concern. As a component of emergency preparedness and planning, the WHO and many national public health agencies have established stockpiles of influenza antiviral agents for pandemic influenza treatment, prophylaxis and outbreak control. 1, 2 In the 2009-10 influenza A H1N1 pandemic, neuraminidase inhibitors (NIs) were the main class of influenza antiviral medications used, with predominant use of the NI oseltamivir, and NIs were among the only influenza-specific pharmaceutical interventions available prior to the development of the H1N1 vaccine. 3, 4 The rationale for stockpiling influenza antivirals is based upon their safety and effectiveness in influenza treatment and prophylaxis; yet, much controversy exists regarding the utility of NIs. A systematic review (SR) which aimed to examine the association between financial conflicts and study results identified 26 published SRs regarding NI effectiveness or safety as of May 2014, with differing conclusions. 5 Since then, several recent, high-profile and notable SR and/or meta-analyses (MAs) in the field have been published, 2, 3, 6 including a methodologically rigorous SR/MA by the Cochrane Collaboration. 2 The Cochrane review 2 challenged the current practices of NI use in seasonal influenza treatment, prophylaxis and establishment of government stockpiles for V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
pandemic influenza, and prompted a number of agencies and governments to reassess existing NI policies. [7] [8] [9] [10] Given the high number of SR/MAs on the subject, it is increasingly challenging for policymakers and other stakeholders to track and synthesize existing, high-quality evidence from SR/MAs regarding NI effectiveness and safety. While a recent SR from 2013 sought to address this issue by examining evidence regarding NI utility from other published SRs, 11 it did not include many of the recent and relevant SR/MAs in the field, 2, 3, 6 with an end date for its literature search of 2012. Therefore, in our SR, we aimed to comprehensively examine and synthesize the current state of evidence from SR/MAs regarding NI effectiveness and/or safety to inform use of these drugs for influenza treatment, prophylaxis and outbreak control.
Methods
We designed a protocol a priori to address our study objective (see File S1 and Appendix 1, available as Supplementary data at JAC Online). A list of all post hoc protocol changes is provided for the reader in File S2. Additionally, a glossary of all definitions used in this review is provided in File S3.
Search strategy
We conducted a systematic search of the published literature using the following electronic databases: BIOSIS Previews, CINAHL, the Cochrane Library (inclusive of Database of Systematic Reviews, Database of Abstracts of Reviews of Effects and Health Technology Assessment Database), EMBASE, MEDLINE, PubMed and Web of Science. Systematic search criteria were developed by a McGill research librarian (G. G.) in conference with team researchers, and peer reviewed by a separate McGill research librarian. The search terms combined concepts of influenza AND neuraminidase inhibitors AND (systematic review OR meta-analysis) terms; a Venn diagram illustrating the Boolean logic of the search is provided in Figure S1 , and the full search criteria used for each database are provided in File S4. Search results were validated by comparison to an a priori specified sentinel list of relevant SR/MAs initially chosen from an SR of SRs on a relevant topic. 5 Searches were limited to articles written in English or French, and published between 1 January 1995 and 10 November 2015 (inclusive). Although NIs were not licensed for use until 1999, the start date of 1 January 1995 was chosen to ensure that any applicable pre-licensure SR/MA studies were eligible for inclusion. We also conducted a hand search of the reference lists of all included articles to identify any non-indexed articles eligible for inclusion.
Study selection Types of studies
We examined evidence from full-text articles of SR/MA study designs published from 1 January 1995 to 10 November 2015. For the purpose of this review, we defined a 'systematic review' as one that reported: (i) a systematic database search; (ii) a systematic presentation of the number of articles retrieved, number selected for inclusion/exclusion and a summary of the final list of included studies (either in a figure/text); and (iii) a systematic quality assessment. A 'meta-analysis' was defined as a study that utilized a statistical method to combine data across multiple studies.
SR/MAs that did not meet these definitions were excluded, as well as any SR/MA that was identified as: (i) an old/previous version of an included SR/MA; (ii) an incomplete version of an included SR/MA (e.g. a publication of partial SR/MA results where the full version had been published elsewhere); (iii) withdrawn by study authors; or (iv) solely examining any of the following: cost-effectiveness, the uptake or attitudes towards NIs, simulations or mathematical modelling studies, financial conflicts of NI studies, or studies from animals or conducted in vitro.
Types of interventions
We selected studies that evaluated the NIs oseltamivir, zanamivir, peramivir or laninamivir-either in separate analyses or together-when administered in the context of influenza treatment or prophylaxis. For the purpose of this review, 'influenza' was defined as influenza-like illness or laboratory-confirmed disease (any method); NI administration was defined as for 'treatment', where an individual had influenza at the time of administration, and for 'prophylaxis', where a person did not have influenza at the time of administration, either prior to or following contact with a person infected with influenza or a confirmed influenza outbreak.
Types of comparators
Studies that compared the NI intervention(s) with any of the following alone or in combination were eligible for inclusion: (i) another influenza NI, antiviral drug class or regimen; (ii) the standard of care at the time of the study; (iii) placebo; or (iv) no influenza treatment.
Types of participants
We did not restrict the types of participants eligible for inclusion, and selected studies where authors evaluated the intervention among any population. We defined the following a priori priority Canadian subpopulations of interest for stratified analyses: (i) infants and young children (0-59 months); (ii) healthy children and adults, aged 5-64 years, with a normal immune system; (iii) people who are 65 years of age and older; (iv) people living with chronic health conditions; (v) people who are immunocompromised; (vi) women who are pregnant or breastfeeding; and (vii) Aboriginal peoples.
Types of settings
We did not restrict the types of settings included in this review, and studies where authors examined populations in any setting were eligible for inclusion. The following a priori Canadian priority subgroups of interest were identified for stratified analyses: (i) communities; (ii) hospitals; (iii) closed or semi-closed institutional settings (such as hospitals, prisons and long-term care facilities); (iv) residential community-based settings (including hostels, homeless shelters and non-healthcare residential settings); and (v) remote and isolated communities.
Primary outcomes
To assess NI effectiveness for treatment, we examined mortality (all-cause, influenza-related and cause unspecified), hospitalization, ICU admission and pneumonia; to evaluate NI effectiveness for prophylaxis, we examined secondary transmission of symptomatic and asymptomatic influenza. To evaluate NI safety, we examined all adverse events and serious adverse events, where NIs were administered for either influenza indication (treatment or prophylaxis).
Secondary outcomes
We examined time to alleviation of symptoms as a secondary outcome to evaluate NI effectiveness in treatment. We also examined site-specific adverse events (i.e. diarrhoea, nausea, vomiting and psychiatric events) as secondary safety outcomes.
Types of outcome measures
We extracted relative risks/rates (RR), risk/rate differences (RD), odds ratios (OR), hazard rates (HR), weighted mean differences (WMD), 95% CI and P values for all primary and secondary outcomes in which NI effectiveness or Systematic review JAC safety was examined between the intervention and a comparator. Only pooled effect measures representing two or more primary studies were extracted from each SR/MA.
Data collection and analysis

Study selection
Two reviewers (M. K. D. and C. B.) independently reviewed titles, titles and abstracts, and/or the full text of all studies returned via the electronic search to determine study eligibility for inclusion. Articles were excluded by review of title alone or review of title and abstract where exclusion consensus between reviewers was achieved based upon initial review only (i.e. without a consensus meeting); all other articles were subject to fulltext review. Following full-text review, the reviewers met to resolve any discrepancies regarding study eligibility decisions in consensus meetings. If needed, a third reviewer was available to resolve disagreements (C. Q.).
For all SR/MAs deemed eligible for inclusion, we extracted a list of primary studies included within each. Comparisons of primary study lists were made between included SR/MAs. In situations where 100% of the primary studies included in an SR/MA were identified as included in another, individual SR/MA, we examined study outcomes and populations/settings for analyses between the studies. If outcomes and study populations were also deemed identical between the SR/MAs, only the higher-quality SR/MA was included. Quality decisions were based upon the enhanced Overview Quality Assessment Questionnaire (eOQAQ) score, described in further detail below.
Data extraction
We used a standardized, pre-piloted form to extract relevant data from included studies. Two independent reviewers (M. K. D. and N. W.) performed data extraction in duplicate for each SR/MA. Consensus meetings were held to discuss any discrepancies between the reviewers and to resolve conflicts. If needed, a third reviewer was available to resolve disagreements (C. B.).
Quality assessment
Two independent reviewers (M. K. D. and N. W.) assessed the quality of each study based upon the Grading of Recommendations Assessment Development and Evaluation (GRADE) framework. The GRADE risk of bias rating was determined using the validated eOQAQ tool. Scoring of the eOQAQ is based upon a 7 point scale to rank the methods and reporting of an SR/MA, with 7 points being the maximum quality score. 12 Scores of 5 points (representing minor or minimal flaws) were viewed as generally representative of high-quality SR/MAs and categorized as having no serious risk of bias; scores of 3 to ,5 points (representing major flaws) were considered to have a moderate risk of bias; and scores of 1 to ,3 points (representing extensive flaws) were considered to have a serious risk of bias.
In addition to the eOQAQ for examining risk of bias, we used the AMSTAR tool, which combines the eOQAQ with other tools, to evaluate the methodological limitations of SR/MAs of randomized controlled trials (RCTs) on the basis of an 11 point scale (11 " highest quality). 13, 14 As has been used previously for AMSTAR, 15 we considered scores ranging from 5 to 8 points as representative of fair to good quality, and scores of 9 points as representative of good quality. While AMSTAR has not been validated for SR/MAs of observational studies, it is widely accepted as the standard quality form for SR/MAs of RCTs; creation of a new tool (AMSTAR-NRS) to examine the quality of SR/MAs of observational studies is currently underway, but was not published at the time of this review.
Quality scores for other GRADE criteria of study inconsistency, indirectness and imprecision were based upon answers to questions we developed in consultation with the GRADE framework. Inconsistency grades were assessed based upon the level of heterogeneity present between primary study effect measures for the SR/MA's reported primary outcomes. In general, we used a visual inspection of forest plots or analysis of the primary study effect measures for an outcome as a 'gold standard' method for grading inconsistency, since we felt that statistical measures of heterogeneity may not always be representative of actual heterogeneity between studies; however, we also consulted the reported I 2 and P values for heterogeneity, where available. In instances where we determined that the I 2 or P values were truly representative of the heterogeneity observed between the effect measures of the primary studies, we assigned categories as follows: I 2 values of 0.6 or P values ,0.10 for any study outcome were given a grade of 'serious', and I 2 values between 0.4 and ,0.6 or P values between 0.1 and ,0.3 were given a grade of 'moderate'; all other studies received a grade of 'not serious' unless studyspecific effect measures, I
2 or P values were not presented, for which we gave the study a rating of 'unclear'. Indirectness grades were based upon the generalizability of: (i) the study population; and (ii) the reported outcomes to our own objective. Where both study population and outcomes were deemed as not generalizable, we gave the study a score of 'serious'; where only one was generalizable, we gave the study a score of 'moderate'; and where both were generalizable, we gave the study a score of 'not serious'. Imprecision grades were based upon the precision of the pooled effect measures for the SR/MA's reported primary outcomes. In general, we used the GRADE suggested cut-offs for judging effect sizes, 16 and scored SR/MA imprecision as 'serious', where effect measures for reported odds, risk or hazard ratios of .2 or ,0.5 were not significant, 'moderate', where effect measures of .2 or ,0.5 were significant, and 'not serious', where effect measures of .5 or ,0.2 were significant. We also considered evidence of a dose-response relationship in determining the imprecision score; where a dose-response relationship was demonstrated, we revised our determination for imprecision to 'not serious'.
Consensus meetings were held to discuss any discrepancies between the reviewers and to resolve conflicts. If needed, a third reviewer was available to resolve disagreements (C. B.).
Data synthesis
We performed a descriptive analysis of study results stratified by NI indication (treatment versus prophylaxis), outcome, NI drug and subpopulation. To visualize the evidence in aggregate, forest plots were created using the extracted SR/MA effect measures for our outcomes of interest. Within forest plots, results for each subpopulation were displayed in descending order of quality based upon eOQAQ scores, and descending year, where eOQAQ scores were equal. Effect measures for time to alleviation of symptoms that were reported in hours were converted to days for comparison purposes.
We reported data from both crude and adjusted effect measures from observational studies, and the intention-to-treat (ITT) and intention-totreat-infected (ITTI; laboratory-confirmed influenza) populations from RCTs, wherever possible. The ITT population is typically considered the most conservative approach for reporting effects in RCTs and ensures the preservation of randomization (if initially achieved) between the treatment and non-intervention arms; however, effect measures may be attenuated, given that the ITT population is inclusive of individuals that may not adhere to study treatment, or in the case of the present review, did not represent a true case of influenza (i.e. participants with influenza-like illness, regardless of laboratory confirmation status) in situations where NIs were administered for influenza treatment. However, in the current study, reporting in the ITT population may be more representative of NI treatment effectiveness in a clinical setting, when individuals do not receive laboratory confirmation prior to the administration of NI treatment. Reporting of NI effectiveness in the ITTI population has been adopted to more accurately address NI treatment effectiveness among people who represent true cases of influenza; in principle, true cases of influenza would likely be evenly distributed between treatment and non-intervention groups, where initial randomization was achieved. Where we refer to the ITT population in situations of NI prophylaxis and/or outbreak control, the ITT population represents the total population that received NI prophylaxis, regardless of adherence to the prophylaxis regimen; the previous distinction of ITTI does Systematic review not apply to these individuals since they necessarily did not have influenza at the time of study enrolment.
As specified a priori, we did not conduct a meta-analysis to pool extracted effect measures due to: (i) the inappropriateness of combining effect measures in consideration of the anticipated heterogeneity across studies; and (ii) issues with the potential overlap between the primary studies of the SR/MAs, whereby combining pooled effect measures may inadvertently include data from a single primary study more than once.
Results
A flow diagram of the search and results of the review is provided for reference in Figure 1 . After de-duplication, 3723 studies were retrieved from the electronic database search and screened via title. Of these, 1444 (38.8%) were screened by title and abstract, 847 (22.8%) were screened via full-text review, and 26 (0.7%) SR/MAs 2,3,6,17-39 were determined eligible for inclusion. From the hand search of the 26 included references, one additional SR/MA 40 was identified for inclusion, for a total of 27 included SR/MA references.
Limitations of the available literature
We were unable to find any SR/MA that provided pooled effect measures for the NIs peramivir or laninamivir. We also did not find literature to address all a priori subpopulations and settings. Furthermore, upon examination of the included studies, we determined that the literature retrieved was not conducive for division using the a priori specified subpopulations. Therefore, the following post hoc mutually exclusive subpopulations were created for stratification: (i) general population, defined as populations that overlap any subpopulation criteria (i.e. inclusive of multiple age groups or risk strata); (ii) children, defined as people ,18 years of age; (iii) adults, defined as people 18-65 years of age; (iv) elderly, defined as people 65 years of age; (v) high-risk, inclusive of people living with chronic illness and/or people who are immunocompromised (exact definitions vary between studies); and (vi) women who are pregnant or breastfeeding. These groups were created in consideration of the a priori groups and the available data from the literature retrieved. Where setting was specified, most studies were inclusive of community settings with the exception of two studies that examined NI effectiveness for prophylaxis in long-term care facilities only (i.e. a closed or semi-closed institutional setting), 17, 36 and two studies that examined NI effectiveness and safety among hospitalized patients only.
3,33
Risk of bias in included studies
Overlap between primary studies In total, 492 primary studies were examined across the 27 SR/MAs, with 204 (41.5%) representing RCTs versus 288 (58.5%) representing observational studies. When duplicate primary studies were excluded, the total number of unique primary studies was 312; 68.1% of RCTs were identified as duplicates and excluded (65/204 unique RCTs) versus 14.2% of observational studies (247/288 unique observational studies). On average, 74.8% of the primary studies included within each SR/MA were also included in at least one other SR/MA (median " 83%). Figure S2 shows the proportion of primary studies included in other SR/MAs for each SR/MA, and a detailed matrix that assesses the overlap of primary studies for all included SR/MAs is provided in Table S1 .
Results of the quality assessment
The overall results for the quality assessment are presented in Figure 2 ; individual quality assessment results for each study are provided in Table S2 . In general, nearly half of all studies (48%) presented imprecise estimates judged to be serious, and 37% of studies were determined to have a serious risk of bias (based upon eOQAQ scores). Few studies (7%) were at serious risk for indirectness and 22% of studies had a serious risk of inconsistency.
When stratified by study type, 88% of studies classified as MA alone were determined to be at serious risk of bias. 23, 29, 31, 32, 35, 38, 40 This determination was mostly attributable to insufficient reporting of study search strategies or criteria for study inclusion/exclusion. Among the MAs that also included an SR, only 13% were determined to be at serious risk of bias. 21, 26 The mean AMSTAR score of included studies was 6.2 (median " 7), which represented a quality score of fair to good. In comparison with eOQAQ, all studies that received an AMSTAR ranking of good (9 points) were also determined as not at risk of serious bias (5 points) on the eOQAQ scale. 2, 3, [17] [18] [19] [20] 25, 27, 28, 33, 39 Literature synthesis NI effectiveness for treatment Mortality Only 3 of 27 studies (11.1%) provided pooled effect measures for the outcome of mortality (cause unspecified); 3, 24, 33 all three studies included data from observational studies. Muthuri et al. 3 presented data from a meta-analysis of pooled individuallevel data, which included datasets from 78 centres and Systematic review approximately 30000 hospitalized patients from the general population; using the individual-level data, the authors were able to present effect measures for mortality adjusted for patient treatment propensity (by quintile), corticosteroid use and antibiotic use. In the remaining two studies, 24, 33 authors combined effect measures directly from primary studies, and also performed stratified analyses by pooling adjusted study effect measures only, where possible.
A forest plot of the meta-analysed estimates for mortality among hospitalized patients that received NI treatment compared with no treatment is presented in Figure 3 ; adjusted estimates are presented in place of unadjusted estimates where available. In the general population, the odds of mortality were consistently lower among hospitalized individuals receiving NI treatment versus no treatment, with a significant reduction in the odds of mortality found in all but one of the study populations. 33 Estimates among participants with influenza-like illness (i.e. clinically diagnosed influenza) versus laboratory-confirmed influenza were similar according to Muthuri et al.; 3 all other estimates were derived from participants with influenza-like illness. 24, 33 Stratified estimates within the general population for adolescents/adults 3, 33 and an estimate for pregnant women 3 were consistent with that of the general population; however, no significant reductions in the odds of mortality among children were observed. 3, 33 The odds of mortality were also examined by timing of NI administration among hospitalized patients with influenza-like illness ( Figure S3) ; adjusted estimates are presented in place of unadjusted estimates where available. Significant and consistent reductions were found in the odds of mortality among the general population, adolescents/adults in the general population and pregnant women that received early (48 h) administration of NIs compared with late (.48 h) administration. A reduction in the odds of mortality was not significant among children in an adjusted study by Muthuri et al. (2014) , 3 but a significant reduction was observed in the unadjusted estimate from an earlier study by Muthuri et al. 33 Trends in subpopulations were similar for subpopulation stratified estimates for adolescent/adults and children admitted to an ICU; 3 Muthuri et al. 33 estimated a significant decrease in mortality among the general population of ICU patients that received early versus late NI treatment.
Only Hsu et al. 24 examined NI effectiveness among all patients (hospitalized and non-hospitalized) with influenza-like illness. No significant difference was found in the pooled, unadjusted odds of mortality among the general population that were treated with oseltamivir versus no treatment (data not shown, OR 0.51, 95% CI 0.23-1.14).
Hospitalization/ICU admission Five studies 2, 6, 20, 21, 24 were used to examine the effectiveness of NI treatment versus no treatment on all-cause hospitalization. Pooled odds or risk ratios from four of these studies 2, 6, 21, 24 are included in Figure 4 ; the remaining study 20 was excluded from the figure because it only presented risk differences.
Among the general population, significant decreases in the odds of hospitalization comparing oseltamivir treatment versus no treatment were observed in adjusted and unadjusted effect measures among the influenza-like illness population presented by Hsu et al., 24 and among the ITTI adolescent/adult population presented by Dobson et al. 6 No significant differences in hospitalization were observed for patients on oseltamivir in the ITT 6 were comprised of overlapping populations for 7/8 of the same primary studies; however, the reported data for these overlapping studies were inconsistent, as Dobson et al. 6 reported 13 fewer hospitalizations in the oseltamivir group and 1 fewer hospitalization in the placebo group. The effects of zanamivir treatment 24 and treatment with NIs generally 21 compared with no treatment were only examined in one study each; no significant reduction in hospitalization was found for either study.
Only Jefferson et al. 2 examined the effect of oseltamivir treatment compared with no treatment on hospitalization among children; no significant difference in hospitalization risk was found.
Few data were reported for ICU admission (data not shown), 24, 33 with data only arising from SR/MAs that included observational studies that examined ICU admission among influenza-like illness patients as a composite outcome. Muthuri et al. 33 reported mostly crude effect measures for ICU admission combined with mortality; Hsu et al. 24 reported on the composite outcome of ICU admission, respiratory failure or mechanical failure. In their only adjusted analysis for the outcome, Muthuri et al. Pneumonia A forest plot for pneumonia (definition inclusive of unverified self or investigator-reported pneumonia) is presented in Figure 5 . In four studies, 2, 6, 18, 24 authors provided relative effect measures comparing the odds or risk of pneumonia among participants receiving oseltamivir treatment versus no treatment; two of these studies were also used to examine the effect of zanamivir treatment versus no treatment. 2, 18 In addition to these (data not shown), Ebell et al. 20 examined the difference in risk of pneumonia among participants receiving oseltamivir treatment versus no treatment, and two studies 21, 33 examined the odds of pneumonia for NIs generally compared with no treatment.
Among the general population, oseltamivir treatment was associated with a reduced risk/odds of pneumonia for the unadjusted estimate among the influenza-like illness population presented by Hsu et al., 24 the ITT/ITTI estimates for adolescents/ adults provided by Dobson et al., 6 the ITT adolescent/adult population in Jefferson et al.,
2 and the ITTI adolescent/adult population in Ebell et al. 20 (data not shown, RD #0.9, 95% CI #1.7 to #0.1). No differences in the risk of pneumonia were observed for the populations examined by Burch et al., 18 the ITT adolescent/adult population by Ebell et al. 20 (data not shown, RD #0.6, 95% CI #1.7 to 0.4), or Hsu et al.'s 24 adjusted or stratified estimates. Zanamivir treatment was not associated with a difference in the odds or risk of pneumonia for any study. 2, 18 In the two SR/MAs that examined NI treatment generally, Falagas et al. 21 found no significant difference of pneumonia in the ITTI population (RR 0.56, 95% CI 0.10-3.16), but Muthuri et al. 33 found a significant increase in the crude odds of pneumonia for participants treated with NIs compared with no treatment (OR 2.29, 95% CI 1.16-4.53); in the same study, no association was found when estimates provided were In three studies, authors examined the effect of oseltamivir treatment versus no treatment on pneumonia in children;
2,18,24 of these, only one identified a significant reduction in pneumonia among oseltamivir-treated participants. 24 Only one study examined zanamivir treatment among children; no significant difference in the risk of pneumonia was found. 
Systematic review
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One study 18 examined the odds of pneumonia among high-risk participants treated with oseltamivir and zanamivir. No differences were observed for participants treated with either NI.
Time to alleviation of symptoms Time to alleviation of symptoms was examined among SR/MAs of RCTs for oseltamivir and zanamivir and presented in Figure 6 . Five SR/MA examined the standardized mean difference in the median/mean time to symptom alleviation between people treated with oseltamivir versus no treatment; 2, 6, 18, 20, 25 four studies examined this measure for zanamivir. 2, 18, 19, 29 Among the general population, treatment with either oseltamivir or zanamivir was consistently found to significantly lower the median/mean number of days to symptom alleviation among ITT populations by approximately 0.5-1 day. 2, 6, 18, 20, 25 In general, reported effect estimates (data not shown) for the ITTI population were lower than those estimated for the ITT in the general population.
Two studies examined the effects of oseltamivir and zanamivir among children. While Jefferson et al.
2 observed a general decrease in the number of days to symptom alleviation for oseltamivir and zanamivir treatment, the decreases in both groups were not significant. In contrast, Burch et al.
18 observed a significant decrease in both oseltamivir-treated children versus no treatment, and children treated with zanamivir versus no treatment. Of note, the estimates from Jefferson et al. 2 were based upon mean time to alleviation of symptoms, while the estimates from Burch et al. 18 were based upon medians.
Significant reductions in the time to alleviation of symptoms were not observed among elderly or high-risk subpopulations for oseltamivir. 6, 18, 25 For zanamivir treatment, significant reductions in the time to alleviation of symptoms were observed for high-risk populations, 18, 19, 29 but not the elderly population. 18 
NI effectiveness for prophylaxis/outbreak control
Secondary transmission
Secondary transmission following prophylaxis with either oseltamivir or zanamivir compared with no prophylaxis in the general population was examined in four studies ( Figure 7) . 2, 26, 28, 34 In SR/MAs that examined administration of preexposure prophylaxis only, 2,28 oseltamivir or zanamivir prophylaxis was administered for a period of 4 weeks (where known) in a setting in which an influenza outbreak was ongoing. In SR/MAs that examined administration of post-exposure prophylaxis only, 2, 26 the duration and timing of NI prophylaxis in primary studies was largely unspecified, though most primary studies were from exposures that occurred in households. Two SR/MAs 26,34 evaluated secondary transmission within community settings only, but effect estimates from the two other SR/MAs 2,28 included at least one primary study from a non-community setting (i.e. healthcare setting, elderly residential homes or long-term care facilities). In situations of pre-exposure and post-exposure prophylaxis, oseltamivir or zanamivir consistently and significantly lowered the odds or risk of symptomatic influenza in all four studies. 2, 26, 28, 34 Two of these studies 2,28 also examined the transmission of asymptomatic influenza. Prophylaxis with either oseltamivir or zanamivir did not reduce the odds or risk of secondary transmission of asymptomatic influenza transmission in either study.
Secondary transmission was also examined only in long-term care facility settings in two SR/MAs 17, 36 (data not shown). Of these, one SR/MA 17 compared zanamivir with rimantadine for prophylaxis in outbreak settings and found that zanamivir prophylaxis significantly lowered the risk of contracting lab-confirmed influenza A (RR 0.22, 95% CI 0.07-0.68). The other SR/MA 36 examined NI prophylaxis compared with no intervention in outbreak settings and found no reduction in the odds of secondary transmission of either influenza A alone or influenza A or B among NI recipients (OR influenza A 1.55, 95% CI 0.62-3.98; OR influenza A or B 1.27, 95% CI 0.56-2.76). Neither analysis was stratified to examine or compare pre-versus post-exposure prophylaxis.
NI safety
All and serious adverse events Adverse events and serious adverse events are presented in Figure 8 . In general, the risk or odds of adverse events and serious adverse events did not significantly differ between persons receiving NI treatment/prophylaxis in comparison to those not receiving NIs across all subpopulations. In one study 18 authors reported a decrease in the odds of all adverse events among persons receiving zanamivir, while authors of another study 24 reported a reduction in the odds of serious adverse events among individuals treated with oseltamivir. Wang et al. 39 evaluated adverse events and serious adverse events as risk differences among children (data not shown); consistent with other studies, no difference was found between children receiving NIs generally (oseltamivir or zanamivir) for treatment compared with no treatment (adverse events, RD #0.03, 95% CI #0.07 to 0.01; serious adverse events, RD 0.00, 95% CI 0.00 -0.01).
Site-specific adverse events The odds or risk of site-specific adverse events are presented in Figure 9 .
Diarrhoea Five studies 2, 6, 21, 23, 25 examined diarrhoea among the general population receiving NIs for treatment or prophylaxis. In three studies, 2,6,25 participants receiving oseltamivir treatment had lower odds or risk of diarrhoea in comparison with no treatment; no effect was observed in the remaining effect measures presented. In two studies, 2,39 authors examined diarrhoea among children receiving NI treatment (data not shown). In one study, 2 no difference was found in the risk of diarrhoea among children treated with oseltamivir or zanamivir (oseltamivir RR 0.87, 95% CI 0.58-1.28; zanamivir RR 0.52, 95% CI 0.15-1.75); in the other study, 39 a borderline significant decrease was found in the risk of diarrhoea among children receiving NIs generally (oseltamivir or zanamivir) compared with no treatment (RD -0.01, 95% CI -0.03 to 0.00).
Nausea and vomiting Four studies 2, 6, 23, 25 included examination of the odds or risk of both nausea and vomiting symptoms among the general population receiving oseltamivir compared with no treatment. Effect estimates from all studies estimated 1.5-2.5 times higher odds or risk of each symptom among people receiving oseltamivir treatment. Another study 26 that examined the risk differences of nausea and vomiting between participants receiving oseltamivir versus no treatment (data not shown) also found a significant increase for both symptoms (nausea RD 5.0%, 95% CI Systematic review 1.4%-8.6%; vomiting RD 1.7%, 95% CI 0.2%-3.3%). In the only study 2 where nausea and vomiting were evaluated as separate outcomes when oseltamivir was administered for prophylaxis, the risk of nausea was significantly higher, but only a non-significant increase was found in the risk of vomiting among participants receiving oseltamivir.
Three studies 2, 21, 28 evaluated the risk of nausea and vomiting together as a composite outcome (data not shown). In the two studies 21, 28 where oseltamivir was examined, one study 28 found a significant increase in nausea and vomiting and evidence of a dose-response relationship between high and low doses of oseltamivir administered for prophylaxis (oseltamivir Systematic review JAC versus no prophylaxis RR 1.48, 95% CI 1.86-2.33; high-versus low-dose oseltamivir prophylaxis RR 2.17, 95% CI 1.52-3.09); the other study 21 found a non-significant increase in nausea and vomiting among participants treated with NIs generally (oseltamivir or zanamivir) versus no treatment (RR 1.78, 95% CI 0.91-3.45). Zanamivir treatment and prophylaxis compared with no use was only evaluated in one study; 2 a significant decrease in the risk of nausea and vomiting was found for persons receiving zanamivir for treatment (RR 0.60, 95% CI 0.39-0.94), while no effect was found among persons receiving zanamivir for prophylaxis (RR 0.88, 95% CI 0.66-1.18).
In two studies 2,39 the risk of nausea and/or vomiting was evaluated among children receiving oseltamivir or zanamivir treatment (data not shown). The risk of vomiting in children treated with oseltamivir compared with no treatment was significantly higher in both studies (Jefferson et 39 vomiting only, RD -0.00, 95% CI -0.02 to 0.02).
Psychiatric events Three studies 2, 6, 23 examined the risk of psychiatric events. None of the studies detected a significant difference for psychiatric events of NI use compared with no NI use during the period that participants were taking NI drugs. However, Jefferson et al.
2 observed a significant increase in the risk of psychiatric events for participants taking oseltamivir for prophylaxis when the on-and off-treatment follow-up periods were combined (data not shown, RR 1.80, 95% CI 1.05-3.08). Figure 9 . The odds or risk of site-specific adverse events diarrhoea, nausea, vomiting or psychiatric events comparing neuraminidase inhibitor (NI) use with no NI use among the general population; unless otherwise noted, effect measure represent risk ratios, and administration of NI for treatment. Within each subpopulation, studies are listed in descending order of quality based upon eOQAQ scores, and descending year, where eOQAQ scores are equal. Footnote symbols:
OR , odds ratio; 1 , stratified estimates for adolescents/adults (12 years of age); P , prophylaxis; *, neuropsychiatric events combined.
Systematic review no significant differences in mortality observed between participants receiving NI treatment compared with no treatment, and only one of two studies showing a reduction in mortality when early NI treatment was compared with late NI treatment. No differences in mortality were observed among children treated in the ICU either. There was insufficient evidence to examine NI effectiveness on mortality among the entire (hospitalized and nonhospitalized) population, the elderly or high-risk subpopulations.
Hospitalization/ICU admission
The evidence of the effect of NIs on the odds or risk of hospitalization was not conclusive. Although all studies that examined NI treatment compared with no treatment among the general population showed a reduction in hospitalization, the observed decrease was not significant in two of four studies; in one of the studies that showed a significant decrease in the risk of hospitalization, the reduction was only observed among the ITTI population, but not the ITT population. One SR/MA based upon crude observational data examined effectiveness of NI treatment on hospitalization among children; no significant difference was detected and while the estimate was largely imprecise, the effect estimate did not favour NI use. There was insufficient data to properly assess NI effectiveness against ICU admission.
Pneumonia
Among the general population, the effectiveness for NIs in the prevention of pneumonia was mixed, though generally favoured a reduction in pneumonia for oseltamivir. Three out of four studies found a reduction in the odds or risk of pneumonia among participants treated with oseltamivir, though the reduction was not consistent in the adjusted estimate or among stratified estimates for adolescents/adult populations from one of the studies that utilized observational data. Among SR/MAs that evaluated RCTs, most diagnoses of pneumonia within these trials did not rely upon a standardized medical definition of pneumonia and often reports for this outcome were unverified (i.e. no confirmatory testing) and reported by participants or investigators. 2 No differences were found in the odds or risk of pneumonia among participants in the general population treated with zanamivir versus those not receiving treatment; however, all effect measures were highly imprecise. In children, oseltamivir treatment was associated with a reduction in the odds of pneumonia in one SR/MA based on observational data, but was not significant in two others that utilized data from RCTs; only one study examined zanamivir effectiveness among children and did not demonstrate a significant effect. No difference in the odds or risk of pneumonia was found for high-risk populations treated with either oseltamivir or zanamivir.
Time to alleviation of symptoms
Significant decreases of approximately 0.5-1 day were observed in the mean/median time to alleviation of symptoms in both oseltamivir-and zanamivir-treated groups in comparison with persons who did not receive treatment.
Among children, one of two studies found a significant reduction in the time to alleviation of influenza symptoms for oseltamivir and zanamivir treatment; the number of primary studies included in each of these analyses was low (n " 2 or 3), and represented a large population of asthmatic children. It should also be noted here that the two SR/MA studies based their estimates on different underlying analyses, i.e. one compared the mean time to alleviation of symptoms (non-significant effect) 18 versus the other study which compared the median time to alleviation of symptoms (significant effect). 2 It has been suggested that median differences may be more meaningful to provide an assessment of clinical utility, since the distribution of time to alleviation data are unlikely to follow a normal distribution. 39 However, others have suggested that means may be more conservative given that medians necessitate rounding to 0.5 increments, and may inadvertently exaggerate the treatment effect compared with mean values. 19 In this context, it should be noted that the time to alleviation of symptoms for oseltamivir trials was typically reported in hours, while zanamivir trials typically reported in days. It is likely that where median times were estimated in hours, the effect of rounding to 0.5 increments is less problematic than median times estimated in days.
Among the elderly, no differences were observed in time to alleviation of symptoms for either drug. Oseltamivir was not associated with significant reductions in time to alleviation of symptoms among high-risk subgroups; however, zanamivir was found to reduce time to alleviation of symptoms in all three studies that examined zanamivir effectiveness in this subgroup.
NI effectiveness for prophylaxis/outbreak control Secondary transmission
Significant and consistent reductions in the odds or risk of secondary transmission of symptomatic influenza were observed for persons receiving either oseltamivir or zanamivir prophylaxis both prior to or following a known influenza exposure. No reductions were found in the odds or risk of contracting asymptomatic influenza, however, among these groups. Estimates were not provided by subpopulation.
NI safety All or serious adverse events
In general, treatment or prophylaxis with either oseltamivir or zanamivir was not associated with an increase in the risk or odds of adverse events or severe adverse events among the general population, children or high-risk persons. One study found a significant reduction in severe adverse events among participants treated with oseltamivir.
Site-specific adverse events
Diarrhoea In general, use of oseltamivir or zanamivir did not increase the risk of diarrhoea. There was some evidence to suggest a possible decrease in the risk of diarrhoea among those receiving treatment with oseltamivir compared with no treatment, with reductions observed in three out of five studies. One of two studies in children also suggested a benefit of NIs in the risk of diarrhoea, with a borderline significant decrease among children receiving NIs generally (oseltamivir or zanamivir) for treatment.
Systematic review JAC Nausea and vomiting Although NIs were not associated with an increase in all adverse events, when symptoms of nausea or vomiting were evaluated separately, a strong and consistent increase of 1.5-2.5 times the risk or odds of each of these symptoms was detected among participants receiving oseltamivir compared with no use. Evidence of a dose-response relationship for the composite outcomes of nausea and vomiting was also observed for persons receiving oseltamivir high-versus low-dose prophylaxis. No similar effects were found for zanamivir. These findings may have implications regarding the utility of oseltamivir treatment or prophylaxis in otherwise healthy individuals, who are at lower risk of serious complications or outcomes from influenza.
Psychiatric events
In general, no significant effects were observed in the risk of psychiatric events among participants receiving NIs compared with no NI use, although data were limited to three SR/MAs with large overlap between SR/MA primary studies. In the SR/MA by Jefferson et al.,
2 a non-significant elevated risk of psychiatric events was found for oseltamivir prophylaxis; when data for this outcome was pooled for the on-and off-treatment follow-up periods, the effect became significant. No effect was seen for zanamivir, though many of the effect measures examining the risk for either drug were largely imprecise. More data is needed to conclusively rule out an effect of NI use on the risk of psychiatric adverse events.
Comparison with previous findings
Our results update the conclusions of a previous SR of SRs by Michiels et al. published in 2013. 11 Similar to Michiels et al., for the outcome of time to alleviation of symptoms, we found NI treatment to be effective at reducing symptom duration by approximately 0.5-1 day among the general population, and zanamivirbut not oseltamivir-to be effective among high-risk populations, while neither drug was effective in the elderly. However, while Michiels et al. reported a reduction in symptom duration among children, our results were mixed due to additional data provided by a 2014 Cochrane review. 2 For pre-or post-exposure prophylaxis, similar to Michiels et al., we found that NIs are likely to reduce secondary symptomatic influenza transmission. Likewise, we found significant increases in nausea and vomiting adverse events among children and adults on oseltamivir, but not zanamivir.
The most meaningful difference between our SRs is that we found NIs are likely to be effective at reducing mortality among the hospitalized, general population. Our results are based upon evidence from SR/MAs that utilized observational studies, which were excluded from the Michiels et al. design.
11 Although potentially more prone to bias, particularly confounding, evidence from adequately designed SR/MAs of observational studies (e.g. Muthuri et al.
3
) can provide key NI effectiveness/safety data for rare outcomes that RCTs are insufficiently powered/designed to address.
Findings from recent SR/MAs not included in the literature search
Since the conclusion of our literature search in November 2015, we have identified at least four recently published SR/MAs that address NI effectiveness and/or safety. 4, [41] [42] [43] Given that the results of these SR/MAs are highly relevant to examine the effect of NI treatment on the risk of mortality, pneumonia and/or hospitalization, we briefly summarize their findings and discuss relevant implications.
In their health technology assessment, Heneghan et al. 42 reported results from the Cochrane SR/MA by Jefferson et al.,
2 as well as the results of a separate SR/MA they conducted to examine the effect of oseltamivir treatment on mortality during the 2009 influenza pandemic using observational data. In the latter SR/MA, the authors summarize evidence from effect measures reported in 30 studies, and conducted an individual-level pooled meta-analysis of data from four of these studies. The authors stratified data from the 30 studies by the odds of treatment in order to examine the risk of time-related biases, based upon the premise that bias away from the null would be more apparent in studies where participants had a higher odds of treatment because untreated patients that died before treatment initiation would have a greater influence on study effect measures. After stratification, the authors found that oseltamivir treatment was associated with a reduction in the odds of mortality (OR 0.56, 95% CI 0.40-0.79) in studies with greater treatment odds, and found no association in studies with lower treatment odds (OR 1.16, 95% CI 0.88-1.54). Based on these findings, the authors concluded that these data were supportive of the presence of time-related bias, which bias observed NI treatment effects for mortality away from the null. In their individuallevel pooled MA, the authors did not find an association between oseltamivir treatment versus no treatment and the odds of mortality after adjustment for confounders using various statistical methods. In their analyses examining early versus no oseltamivir treatment, however, the authors did find that early oseltamivir treatment significantly reduced the odds of mortality when the data were analysed via standard logistic regression analyses, but no association was apparent when regression models were used that accounted for the effect of time. Based on their results, the authors concluded that there was insufficient evidence to support an effect of oseltamivir treatment on the risk of mortality among 2009 pandemic influenza patients.
Muthuri et al. 43 conducted an individual-level pooled metaanalysis to examine NI treatment on pandemic influenza-related pneumonia (confirmed by chest radiography) among hospitalized patients. Using a similar dataset and methods as in their earlier study, 3 they did not find a significant reduction in pneumonia among patients treated early with NIs versus no NI treatment for lab and/or clinically confirmed influenza (lab and clinically confirmed, adjusted OR 0.83, 95% CI 0.64-1.06; lab confirmed only, adjusted OR 0.83, 95% CI 0.64-1.08). The authors did, however, find a significant reduction in pneumonia among patients receiving early versus late NI treatment (lab and clinically confirmed, adjusted OR 0.43, 95% CI 0.37-0.51; lab confirmed only, adjusted OR 0.44, 95% CI 0.38-0.52). Among patients with pneumonia, the authors also found that early versus late NI treatment was associated with a significant reduction in the adjusted odds of mortality (OR 0.70, 95% CI 0.55-0.88) and ventilation support (OR 0.68, 95% CI 0.54-0.85), but no difference for admission to the ICU (OR 0.89, 95% CI 0.71-1.11) or acute respiratory distress syndrome (OR 0.65, 95% CI 0.38-1.11); no significant differences were detected for any of these outcomes when the authors compared early versus no NI treatment among these patients. The authors conclude that early NI treatment likely reduces the risk of pneumonia among hospitalized patients, but reinforced the need for welldesigned observational studies to evaluate NI effectiveness.
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A recent SR by Boikos et al. 4 examined NI use in situations of pandemic and/or novel influenza. While the authors did not conduct an MA, their findings were similar to previous SRs of observational data, 3, 24, 33 and the authors concluded that NI treatment is likely to be effective at reducing mortality and pneumonia, with a greater benefit observed where NIs were administered within 48 h of influenza-like symptoms. The authors also found that NI prophylaxis was likely to reduce secondary transmission of influenza, and likely safe to use in the general population.
Finally, Venkatesan et al. 41 conducted an individual-level pooled MA among patients with 2009 pandemic influenza to examine the risk of hospitalization where NIs were administered in the outpatient setting. Their data set was largely representative of patients who had severe pandemic influenza who were at highrisk of hospitalization; however, among this population, the authors found that both NI treatment versus no NI treatment and early versus late NI treatment reduced the risk of hospitalization among outpatients, after adjustment for potential confounders. The authors concluded that their data were suggestive that outpatients with severe pandemic influenza should receive NI treatment to reduce the risk of hospitalization.
Taken together, the results of these SR/MAs are generally supportive of the effectiveness of NI treatment to reduce the risk of pneumonia among hospitalized patients 43 and the risk of hospitalization among high-risk outpatients with severe disease. 41 Heneghan et al., 42 however, do raise important issues with regard to time-related biases in the examination of NI treatment that should further be explored via simulations and future research.
Limitations of the review
It is important to consider the results of our review with regard to several limitations. First, we found significant overlap between the primary studies included in many of the reviews. While our results appear to draw upon data from numerous studies and populations, many of these studies may in fact have used much of the same data to produce summary estimates. In order to minimize this potential bias, we excluded studies for which there was 100% overlap between the primary studies, outcomes and populations; however, this does not preclude studies with overlap of ,100%.
Second, the majority of SR/MAs included in this review were reliant upon data from RCTs. While some of these SR/MAs reported effect measures in both ITT and ITTI populations, others only reported measures for either population, making it difficult to compare results between studies. Recently, the merit of reporting of the ITTI population for oseltamivir was questioned by Jefferson et al.
2 when laboratory confirmation was based upon an increase in antibody titres from baseline. In their SR/MA, Jefferson et al. found a significantly lower increase in antibody titre among people following treatment with oseltamivir compared with placebo, and hypothesized that oseltamivir may limit the host's antibody response to influenza; if these findings are accurate, estimates from the ITTI population may produce bias effect estimates where those truly infected with influenza are not equally identified in the treatment and placebo arms. As a result of this and other considerations, we report results for both ITT and ITTI populations, wherever feasible.
Another limitation of using SR/MAs that primarily derived data from RCTs is the potential limited generalizability of RCT study populations. We found that SR/MAs that included only RCTs were likely to score lower on our quality assessment for indirectness, since participants were deemed to be younger and healthier than the general population. Furthermore, we found that effect measures from these SR/MAs of RCTs for our study outcomes occurring at a low frequency (e.g. hospitalization, pneumonia) were often imprecise; and overall, more than 90% of the SR/MAs included in this review were judged to have moderate to severe risk of imprecision. Although we also included SR/MAs that examined observational data in an effort to improve the generalizability and precision for rare outcomes of our findings, most SR/MAs included in this analysis relied upon RCTs alone.
For the outcome of mortality, we were only able to identify data among hospitalized patients from three SR/MA that drew upon results from observational studies. While observational data may be better to examine rare outcomes, a limitation of these SR/MAs was that the primary evidence may be more prone to potential biases, particularly confounding. Of the three SR/MAs that were able to examine mortality, only one was able to provide estimates that were likely less prone to confounding biases by using individuallevel pooled data with adjustment for the propensity of treatment to address confounding. In an effort to avoid bias from confounding, we reported adjusted measures from SR/MAs of observational studies, wherever available.
Another limitation of observational data is that effect measures solely comparing NI versus no treatment may not reflect the role of timing of NI administration on NI effectiveness. 3, 41 For example, in several studies, NIs given more than 48 h following the onset of influenza symptoms appear to be less effective than NIs given within 48 h of symptom onset. 3, 4, 33, 41, 43 In situations where patients are selectively given NIs based on their clinical indication (e.g. admission to the ICU) and patients with that clinical condition are more likely to receive NIs beyond their period of maximum effectiveness, measures of effectiveness comparing NI treatment versus no treatment may be biased toward the null or even in the opposite direction. On the contrary, as recently proposed by Heneghan et al., 42 time-related biases could work to bias effect measures away from the null in favour of NI effectiveness where more severe patients are likely to experience the outcome quickly, before they have the opportunity to receive NI treatment, thereby making NIs appear protective. While we were unable to address issues related to potential time-related biases in our analyses, these biases should be considered in the design of future observational studies, and examined further via simulations. In our review, while we included observational data, for all outcomes with the exception of mortality, our analyses were more likely to rely upon data from RCTs that had strict eligibility criteria with regard to the timing of NI administration, making them less prone to timerelated biases.
Finally, our data were limited in their ability to address NI effectiveness and safety among all populations and settings of interest, and we did not find any data for peramivir or laninamivir. Furthermore, most primary studies were conducted during periods of seasonal influenza, and thus may impact the generalizability of results to pandemic or novel influenza settings. We also regret that we were unable to examine all potentially relevant outcomes related to NI effectiveness or safety; however, we attempted to present data for any outcomes deemed particularly relevant in the context of public health, in consideration of the data available.
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Conclusions
Among the general population, NI treatment is likely to be effective at reducing mortality in hospitalized individuals and reducing the time to alleviation of influenza symptoms by approximately 0.5-1 day. Data for NI effectiveness against hospitalization and pneumonia were mixed and largely imprecise, though treatment with oseltamivir generally favoured a reduction in unverified pneumonia within the general population. There was insufficient evidence to examine NI effectiveness against ICU admission, as well as death among non-hospitalized individuals.
Where administered for pre-or post-exposure prophylaxis, both oseltamivir and zanamivir lowered the rate of secondary transmission of symptomatic influenza, but did not demonstrate an effect on secondary transmission of asymptomatic influenza.
Treatment or prophylaxis with NIs was not associated with an increased rate of adverse events or serious adverse events. Participants treated with oseltamivir appeared to have a lower risk of diarrhoea compared with those not receiving treatment. However, both oseltamivir treatment and prophylaxis were consistently associated with a 1.5-to 2.5-fold elevated risk/odds of each nausea and vomiting symptoms compared with no treatment; an elevated risk of nausea or vomiting was not observed with zanamivir use. These data may have implications for using oseltamivir to treat or prevent influenza among persons who are at low risk of serious complications. More data is needed to conclusively rule out an effect of NI use on psychiatric events.
Overall, data on NI effectiveness and safety from subpopulations was limited, and the conclusions from this review are only applicable to the general population. Data from SR/MAs predominantly came from RCTs, potentially compromising generalizability and limiting the power to examine rare outcomes.
Given these data, for the general population, we recommend that decisions regarding NI use for influenza treatment and prophylaxis are made in consideration of the potential adverse events associated with NI use, particularly for persons who are at low risk of influenza complications. Among hospitalized patients, however, early administration of NIs within 48 h of symptom onset seems warranted to reduce the risk of mortality.
